<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28448">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02736383</url>
  </required_header>
  <id_info>
    <org_study_id>2016-60</org_study_id>
    <nct_id>NCT02736383</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Hip Fracture Surgery</brief_title>
  <official_title>Effectiveness of Tranexamic Acid (TXA) in Reducing Blood Loss in Hip Fracture Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Health Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Health Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if TXA utilization is effective at reducing transfusion rates in elderly
      patients undergoing surgery for treatment of a hip fractures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to one of two groups: the intervention group and the control
      group. Participants will be enrolled in the study for 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Transfusion Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Blood transfusion rates during the patients hospital stay will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of stay</measure>
    <time_frame>6 weeks</time_frame>
    <description>The patients length of stay in the hospital will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post operative complications</measure>
    <time_frame>6 weeks</time_frame>
    <description>Post operative complications will be assessed through the 6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization costs</measure>
    <time_frame>6 weeks</time_frame>
    <description>Economic evaluation for inpatient and re-admission will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Hip Fracture</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic Acid 1 gm, IV, twice during surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Tranexamic Acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic Acid, 1 gm, IV, twice during surgery</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Cyklokapron</other_name>
    <other_name>TXA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip
             fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography,
             or magnetic resonance imaging.

          -  Age 65 and older

          -  Low energy mechanism of injury

          -  Hip fracture fixation performed within 48 hours

          -  English speaking

          -  Anticipated medical optimization for operative fixation

          -  No other major trauma

        Exclusion Criteria:

          -  Unable to provide informed consent (dementia, limited decision making capacity)

          -  Admitted by medical service for significant co-morbidities

          -  Unable or refusal to receive blood products

          -  Retained hardware around the affected hip

          -  Infection around the affected hip

          -  Transfer patients with a length of stay &gt; 24 hours at the transferring hospital

          -  History of deep vein thrombosis (DVT) or pulmonary embolus (PE) within the past year

          -  On anticoagulation treatment for DVT or PE, currently or within the past 12 months

          -  Diagnosis of deficient natural anticoagulation

          -  Known congenital thrombophilia (Deficiency of Protein C, S, Antithrombin)

          -  Known allergy to TXA

          -  History of seizure disorder

          -  Cardiac stent or ischemic stroke within 1 year

          -  Concomitant subarachnoid hemorrhage

          -  Active intravascular clotting

          -  Prisoner

          -  Patients undergoing percutaneous pinning of the hip fracture

          -  Patients with renal impairment (serum creatinine &gt;1.5 or creatinine clearance &lt; 50
             ml/min)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blake W Miller, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spectrum Health Hospitals</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 9, 2016</lastchanged_date>
  <firstreceived_date>March 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
